Novome announces positive results from GEMM cell therapy trial

Novome announces positive results from GEMM cell therapy trial

Novome Biotechnologies announced positive results of its phase 1 trial evaluating NOV-001, a once-daily Genetically Engineered Microbial Medicine for the treatment of enteric hyperoxaluria.“This study marks the first time that humans have been dosed with a therapeutically engineered microbe designed to engraft and grow in the human gastrointestinal tract,” Blake Wise, CEO of Novome, told Healio Gastroenterology. “The results of the study show that we can indeed controllably and safely engraft such a cell therapy into the gut.”NOV-001, a Genetically Engineered MicrobialRead More

Share on facebook
Share on twitter
Share on linkedin